RXi Pharmaceuticals (NASDAQ: RXII) Starts Presentation at 2017 Disruptive Growth & Healthcare Conference
RXi Pharmaceuticals (NASDAQ: RXII) is a clinical-stage RNAi company that focuses on discovering and developing therapies primarily in the areas of dermatology and ophthalmology. Its clinical development programs include RXI-109, a self-delivering RNAi compound in phase IIa clinical trial for prevention or reduction of dermal scarring following surgery or trauma, as well as for the management of hypertrophic scars and keloids, and in a phase I/II clinical trial in retinal scarring. RXi is also developing RXI-109 for the treatment of an ophthalmic indication, focusing on retinal and corneal scarring; and Samcyprone, in phase II clinical trial for the treatment of…